The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

about

Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.

P2860

Q38835771-2C47E947-9919-46EA-87F9-551B790BBA08 Q38846325-F132BFB4-BFF4-41C8-8265-413F3FDAC069 Q39217354-76728814-40B3-4B1A-A90B-A26DAE6C29D3

P2860

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Item

http://www.wikidata.org/entity/Q36547224

description

2016 nî lūn-bûn

@nan

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

name

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

@ast

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

@en

type

Item

label

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

@ast

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

@en

prefLabel

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

@ast

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

@en

P1476

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

@en

P2093

Mrinal M Patnaik

http://www.w3.org/2001/XMLSchema#string

Priyanka A Pophali

http://www.w3.org/2001/XMLSchema#string

P2860

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

P304

40-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PPO.0000000000000165

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26841016

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

chronic myeloid leukemia

P932

4742366

http://www.w3.org/2001/XMLSchema#string

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

about

P2860

P2860

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932